TY  - GEN
AU  - Watt,Maureen
AU  - McCrea,Charles
AU  - Johal,Sukhvinder
AU  - Posnett,John
AU  - Nazir,Jameel
TI  - A cost-effectiveness and budget impact analysis of first-line fidaxomicin for patients with Clostridium difficile infection (CDI) in Germany
SN  - 1439-0973
PY  - 2017///0329
KW  - Aminoglycosides
KW  - economics
KW  - Anti-Bacterial Agents
KW  - Clostridioides difficile
KW  - drug effects
KW  - Cost-Benefit Analysis
KW  - Enterocolitis, Pseudomembranous
KW  - drug therapy
KW  - Fidaxomicin
KW  - Germany
KW  - Humans
KW  - Markov Chains
KW  - Recurrence
N1  - Publication Type: Journal Article
UR  - https://doi.org/10.1007/s15010-016-0894-y
ER  -